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Introduction   
A critical function of the unique mucosal immune system of the female genital tract (FGT) is 
to identify and eliminate potentially pathogenic viral and bacterial agents and to provide 
protection against sexually transmitted diseases. Globally it has been estimated that in 
adults between 15 and 49 years of age there were 105.7 million cases of new Chlamydia 
trachomatis sexually transmitted infections (STIs) in 2008 (1). Significant disease sequelae 
following chlamydial infections of the FGT include pelvic inflammatory disease, tubal 
infertility and ectopic pregnancy (2, 3, 4).  
 
The FGT comprises several immune compartments found in the upper genital tract (UGT) 
(endocervix, ovaries, Fallopian tubes and uterus) and lower genital tract (LGT) (ectocervix, 
and vagina). The UGT, with Type I mucosa (5) is lined with a single layer of columnar 
epithelium and the LGT with Type II mucosa is lined with stratified squamous epithelium 
(reviewed in 6).  The transitional zone where squamous epithelium changes to columnar 
epithelium is the most immunologically active site of the FGT. Whilst currently documented 
(relative) microbial sterility is found in the uterus and fallopian tubes, commensal vaginal 
flora such as Lactobacillus crispatus are found in the LGT and are under hormonal influences 
at this site (58). 
  
The human FGT contains components of the innate and adaptive mucosal immune 
responses that are found in various distributions at different sites throughout the tract.   
Figure 1 depicts the FGT anatomy and the location and relative abundances of innate 
immune cells at this mucosal site (6, 7, 8, 33-38).In the FGT the major lymphocyte 
components are NK cells and T lymphocytes including CD3+ T lymphocytes that are present 
in all tissues of the tract. In the LGT the CD8+ and CD4+ are dispersed throughout the 
stroma whilst lymphoid aggregates of these cells are formed in the uterus (9). Granulocytes 
are present and these are principally located in the Fallopian tubes. Finally, relative to T 
lymphocytes, smaller numbers of monocytes and B lymphocytes are found throughout all 
tissues of the FGT (10).   
 
Immune cells at this site express both surface and cytosolic pattern recognition receptors 
(PRRs) including amongst others Toll-like receptors (TLRs) and the nucleotide-binding 
oligomerisation domain (NOD)-like receptors (NLRs). TLRs 2 and 4 are highly expressed in 
the UGT (Fallopian tubes and cervix) when compared with expression levels in the LGT 
(endometrium and ectocervix) whilst TLRs 7, 8 and 9 and NOD-1 (which is involved in 
sensing Chlamydia infection) and NOD-2 are expressed at similar levels throughout the tract 
(11, 12, 13). 
 
In addition to providing a physical barrier for protection, the genital tract epithelial cells 
lining the FGT are immunologically active cells.   For example they  act as key initiators of 
innate and adaptive immunity   by secreting cytokines and chemokines including IL-1b, TNF-
a, IL-6, IL-8 and GM-CSF in response  to human chlamydial infections (14).   
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Host protection of the FGT is afforded by two arms of defense comprising innate and 
acquired immunity.  The cellular components of specific immune responses at this site are T 
lymphocytes expressing αβ- and γδ-T cell receptors (TCR) and immunoglobulins (Ig) 
producing B lymphocytes (15).   Effectors  of non-specific responses include epithelial cells, 
monocytes, macrophages, granulocytes (neutrophils, eosinophils and basophils), dendritic 
cells (DCs) and Natural Killer (NK) cells that confer protection due to chemokines, cytokines 
and phagocytosis. Cells of both the innate and adaptive immune systems are found in 
Fallopian tubes, uterus, cervix and vagina (16). Localisation of T lymphocyte populations in 
the female upper (UGT) and lower (LGT) genital tracts over the menstrual cycle is 
summarised in Table 1(17-39). 
 
Innate host defense particularly in the LGT is provided by the vaginal microbiota maintained 
in a healthy equilibrium (reviewed in (40) as well as by the myriad of antimicrobial peptides 
(AMPs) and protease inhibitors of cervicovaginal fluid (41) and reviewed in (40,42). The 
AMPs and pathogen recognition receptors (PRR) toll-like receptors (TLRs) are key 
intermediaries of innate immunity in the FGT (42-45). 
 
The recruitment and function of immune components of the FGT are precisely regulated by 
hormonal changes during the menstrual cycle by the sex steroids that co-ordinate cell 
trafficking and immune activation at this mucosal site Female sex hormones estrogens, 
progestins and androgens are produced by ovarian cells with levels of estradiol (E2 or 17β-
estradiol) and progesterone or P4 (pregn-4-ene3,20-dione) varying in accordance with 
fluctuations in the menstrual cycle (15). In the menstrual/ovarian cycle of humans the 
endometrium develops and follicles grow until ovulation in the Proliferative/Follicular 
phase. The Secretory/Luteal phase is characterised by high levels of progesterone from the 
corpus luteum to maintain the endometrium. Finally, corpus luteum regression and 
menstruation occurs during the menstrual phase At menstruation, serum E2 levels measure 
typically <50pg/ml. Gradually increasing amounts of E2 are found in the follicular 
(proliferative) phase of the adult female menstrual cycle with serum levels at a pre-
ovulatory stage (day 14) ranging from 110-410 pg/ml and dropping briefly at ovulation. 
Levels of E2 (20-160pg/mol) and P4(>5ng/ml) are present during the luteal (secretory) phase 
from days 14-28 of the menstrual cycle typically peaking at day 21 of the cycle. At the end of 
the secretory phase E2 levels return to their menstrual levels.  
The sex hormones E2 and P4 are key contributors to susceptibility and innate and acquired 
immune responses to bacterial and viral infections of the FGT (46) reviewed in (15); 47,48). 
It is also known that these hormones contribute to the sex-based differences both in innate 
and in acquired immunity and infectious diseases with estrogens affecting levels of 
chemokine receptors by T cells and the higher CD4+ T-cell populations in women 
undergoing  significant changes during the ovarian cycle [reviewed in (49)]. Differences in E2 
levels between male and female mice have also been reported as impacting on the 
expression of inducible nitric oxide synthase (iNOS)(50) and hence the production of nitric 
oxide (NO) a gas that  modulates  production of pro-inflammatory cytokines such as 
interleukin-6 ( IL-6) and  tumour necrosis factor α (TNF-α)(51). 
 
Innate and adaptive mucosal immunity in the FGT are regulated by the female sex 
hormones E2 and P4 and have been reviewed [(15),(52)]. Hormones regulate the transport 
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of immunoglobulins, the levels of cytokines, the expression of TLR genes (53,54) and the 
distribution of immune cells and antigen presentation in the genital tissues during the 
reproductive cycle (16, 43) Figure 2 depicts the Menstrual Cycle phases, sex steroid 
hormone levels and immune cells present in the FGT.  
The afferent and efferent arms of uterine, cervical and vaginal immune responses are 
separately regulated and the control by sex hormones is distinct and species-specific in 
vaginal immune compartments (47). In the human uterus/cervix cellularity and CTL activity 
is menstrual cycle dependent with abundant IgA-secreting cells and secretory component 
(SC) expression in the endocervix. In the vaginal immune compartment cellularity and CTL 
activity is not menstrual cycle dependent, CD8+ T cells dominate and these are vital in a 
response to chlamydial infection  (see review 47) , there is only a minor population of IgA 
plasma cells and low levels of SC expression, and IgG dominates with peri-ovulatory 
antibody peaks (47).  
This review summarises our current knowledge of the effects ofsex hormones E2 and P4 in 
the female genital tract on innate and adaptive immunity, antibody secretion, genital tract 
infections caused by Chlamydia trachomatis and on vaccine-induced immunity. 
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1. Hormonal effects on Innate Immunity  
There are many components of innate immunity operational in the vagina and these have 
recently been reviewed (44, 55) as have components of innate immunity in the ovary and 
endometrium (56). These include soluble factors (such as mannose-binding lectin, 
complement components, defensins, secretory leukocyte protease inhibitor (SLPI) and nitric 
oxide), membrane-associated components such as Toll-like-dependent and -independent 
receptors, as well as phagocytic cells.  The innate immune system of the FGT is also 
comprised of many cells including macrophages, dendritic cells (DCs), neutrophils, NK cells 
and epithelial cells. It is now becoming increasingly apparent that all aspects of innate 
immunity including secretion of protective factors and localisation and function of innate 
immune and non-immune cells,  and receptor expression on epithelial cells (57), vary with 
the release of ovarian steroid hormones over the menstrual cycle. Table 2 (58-71) 
summarises the effects of estrogen (E2) and Progesterone (P4) at the proliferative and 
secretory phases on aspects of innate immunity in the FGT. 
The innate response is triggered by PRRs (including TLRs and non-TLRs such as NOD-like 
receptors) expressed predominantly by immune effector cells such as macrophages, 
neutrophils and DCs that are found in the genital mucosa. These include TLR4 and its co-
receptor Cluster of Differentiation (CD) 14 (chlamydial LPS and HSP60)(72-74) TLR2 
(chlamydial HSP60) (75, 76) and NOD protein, Nod2 (rudimentary proteoglycan motif 
produced by C. trachomatis )(77). Expression of TLR genes 2,3,4,5,6,9 and 10 is reportedly 
significantly higher in human endometrial tissue during the secretory phase (when P4 is the 
predominant hormone) compared to all other phases of the menstrual cycle (46, 68). 
The epithelial layer of the vaginal epithelium (LGT) and endometrium, endocervix and 
fallopian tubes (UGT) is induced to proliferate producing a thickened uterine epithelium 
during the proliferative stage of the menstrual cycle when increased secretion of the E2 
hormone are observed. During the secretory phase of the menstrual cycle when P4 levels 
exceed E2 levels the epithelial layer is reduced in thickness. The human FGT is not as 
permeable as the rodent FGT to antigen uptake during the P4 dominated secretory phase 
since P4 does not significantly reduce the thickness of the vaginal epithelium in humans 
(78). 
 
Rodent FGT 
 
In murine models it has been reported that increased genital infections with C.trachomatis 
are seen in progesterone-treated mice (79). Thus the immune responses to chlamydial 
infections seen in the FGT rodents and humans are likely to be modulated in different ways 
by these vaginal permeability differences. 
 
2. Hormonal effects on antigen presentation 
In the FGT sex hormones regulate both antigen presentation by DCs and also the numbers 
of macrophages and antigen presenting cells found within epithelial cells of uterine and 
vaginal tissues (80,81). Human vaginal tissue contains cells that can present antigen to 
Formatted: Font: Bold
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memory T cells (82) and epithelial cells from uterine endometrium are known to 
constitutively express major histocompatibility complex (MHC) Class II molecules that are 
required to present antigen to T lymphocytes (83). In the rat, E2 enhances antigen 
presentation by uterine epithelial cells (80) whereas in the mouse E2 inhibits epithelial cell 
antigen presentation (81). Mature DCs (mDCs) are characterised by high production of IL-12 
(84) that facilitates the development of gamma interferon producing Th1 cells (85). Estrogen 
has been shown to modulate the expression of cytokines and chemokines in human 
monocyte-derived DCs with mDCs pre-treated with E2 showing an increased ability to 
stimulate naïve CD4+ T cells (86).  E2 can therefore regulate DC effector function and can 
induce and maintain inflammatory responses in the FGT. 
The effects of E2 on the differentiation and function of antigen-presenting cells (APCs) in 
vitro has been reviewed (see 87, 88). Much of the current evidence shows that E2 can 
activate dendritic cells and differentially regulate adaptive immune responses through 
direct effects on DC functions [see (89)]  via E2 receptor (ER) ligands [reviewed in (90)]. It 
has been shown that ER-alpha is the main receptor regulating E2-dependent DC 
differentiation in murine bone marrow derived DCs in vitro (91). At high concentrations 
typical during pregnancy, E2 plus TNF-alpha have been reported to induce a distorted 
maturation of human DCs resulting in an increased capacity to initiate T helper 2 responses 
(92).  
P4 has been shown to inhibit many functions of DC’s (e.g. suppressing TLR mediated 
cytokine production by some subsets of DCs with a recent study focussing on the effect of 
this sex hormone on TLR signalling in DCs (89). These authors state that P4 inhibition of 
plasmacytoid DC (pDC) function may impair specific antiviral responses (e.g. HIV or HSV-2) 
that rely on certain TLR subsets and this inhibition may have a significant impact on global 
health.   P4 is also a potent inducer of semi-mature tolerogenic DCs and is reported to 
inhibit mature DC activity which can ultimately contribute to the induction of pro-
inflammatory responses (93). The effect of sex steroids on the induction and function of a 
recently described CD4Tcell subset, Th17 T cells that are involved in chronic inflammation in 
some disease states (94), is also an area flagged for important future research since P4-
mediated disease remission in autoimmune diseases may involve impaired DC-regulated 
induction of Th17 cells (95). The inhibitory effects of P4 on immature bone-marrow derived 
DCs (BMDCs) in female and male rodents has recently been reported to differ and is likely 
due to differences in P4 receptor protein expression affecting DC function in these animals 
(88). 
A recent review of the functions of DCs and subsets of macrophages in the FGT has also 
addressed the sex hormone regulation of these professional antigen presenting cells at this 
mucosal site (96).  Changes in the populations of DC and macrophage cells in the FGT occur 
due to (i) varying levels of ovarian steroid hormones at this site (97), (ii) the delivery of CpG 
oligodeoxynucleotide (ODN) to the murine genital tract (98) and (iii) the stages of the 
menstrual cycle, noting that the frequencies of macrophages and immature DCs are higher 
in the menstrual phase when compared to other phases of the cycle (99,100).  
In a study investigating genital tract infections of C57BL/6 mice with C.trachomatis serovar D 
it has been reported that in the LGTs of these mice, IL-10 (primarily from CD11b+DC) was 
the dominant interleukin suggesting the presence of Th2 cells in these animals (32). In the 
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UGT’s of these same animals,   a Th1 subset of cells dominated with increased levels of IFN-γ 
expression recorded following genital tract infections of these mice with C. trachomatis  This 
suggests that DCs are major contributors to IL-10 production in the LGT of mice and that 
production of this interleukin likely leads to an anti-inflammatory site of poor Th1 immunity 
at this mucosal site (32). 
 CD16-expressing macrophages and monocytes are also key components of the innate 
immune system of the FGT and are cells that are capable of producing cytokines and 
chemokines upon activation. These cells are also known to be profoundly affected by E2 
[reviewed in (49)]. Studies have shown that E2 uses both estrogen receptor (ER) alpha (ERα) 
and ER beta (ERβ) to decrease CD16 expression on monocytes and hence to alter monocytic 
cytokine release following CD16 receptor activation (101). More recently it has been shown 
that human macrophages predominantly express an N-terminal truncated variant of ERα, 
ERα46, and that this is also regulated by E2 (102). Removal of endogenous E2 has been 
shown to reduce expression of TLR4 on the surface on murine macrophages thus decreasing 
both pro-and anti-inflammatory cytokine releases from these cells. The  addition of 
exogenous E2,  however, corresponded with significantly higher expression of cytokines 
from these cells  highlighting the immuno-enhancing effects of E2 on these cells (103). TLR4-
mediated immune responses in macrophages have recently been reported to be inhibited 
by P4 via suppression of NF-κβ activation suggesting a mechanistic explanation for the 
regulation of innate immune responses of these cells  by this sex hormone (104). 
3.  Roles of Non-conventional APCs in uterine and vaginal tissues in innate immunity 
In the FGT the underlying stromal cells are known to regulate growth and function of 
polarised epithelial cells (ECs) (43) and uterine stromal cells mediate TNF-α release from 
uterine epithelial cells in the presence of E2 (105).  It has also been reported that TLR 1-10 
expression in murine vaginal ECs was significantly increased during the diestrous phase and 
expression of TLR2 was significantly decreased in ECs cultured in the presence of stromal 
cells (106). 
The role of epithelial cells and their associated cytokines in innate immunity of the FGT has 
been well documented [reviewed in (8)] (107).  Sex hormones regulate the estrous cycle in 
rodents and the menstrual cycle in women to optimise mating and fertility and they are also 
involved in regulating innate immunity in the FGT in both rodents and in mammals (105).  
Human oviduct epithelial cells (ECs) express Toll-like receptor 3 and E2 has been reported to 
suppress the TLR-3-induced cytokine and chemokine production in human endometrial 
epithelial cells (108).  Chemokines including CCL20/macrophage inflammatory protein 3α 
(CCL20/MIP-3 α) have been found to have antimicrobial properties (109) and CCL20/MIP-3 α 
is unique in binding exclusively to CCR6 receptor in humans (110). Expression of CCL20/MIP-
3 α has been reported from epithelial cells of the FGT and secretion occurs constitutively as 
well as being induced by inflammatory conditions (111).   
E2 inhibits IL-1β-mediated responses by uterine epithelial cells suggesting that an inhibitory 
effect of E2 may be vital for reducing the pro-inflammatory responses that are mediated by 
these cells (112). E2 also can act on endometrial epithelial cells to suppress TLR3-induced 
cytokines and chemokines (108).  
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The effects of E2 and P4 on the release of antibacterial factors by epithelial cells in the rat 
uterus was studied and it was reported that in ovariectomised rats treated with E2,  
antibacterial activity against S.aureus and E.coli increased in uterine secretions, an effect 
that was reversed with P4 treatments (61).  P4 has been reported to potentiate the E2 
stimulated expression of nitric oxide synthase (NOS) isoforms including endothelial NOS 
(eNOS) in endometrial derived primary and human endometrial surface epithelial cell line 
(113).   P4 has also been reported to stimulate the expression of NOS in endometrial 
epithelial cells  and this may potentially affect infection outcomes at this mucosal  site (114).   
4. Hormonal effects on T lymphocytes in the Female UGT and LGT 
The FGT’s of humans and mice lack underlying organised lymphoid aggregrates (115) 
contrasting with reports of lymphoid cell aggregates in the mucosa of the simian vagina 
(116). Present in the female UGT and LGT are T lymphocytes specifically CD4+ and CD8+ T 
cells, along with antigen presenting cells (APCs) including macrophages and dendritic cells 
(DCs). Immune mediators of cell-mediated immunity are found distributed within distinct 
regions of the female LGT. The cervix is a major inductive and effector site for CMI in the 
lower human female genital tract. In women with no current FGT inflammation 
macrophages and CD4+ and CD8+ T lymphocytes are most prevalent between the ecto- and 
endo-cervix, in the so-called cervical transformation zone (TZ), and also in the surrounding 
tissue. Intraepithelial lymphocytes are predominantly CD8+T cells in the cervical TZ. The 
normal vaginal mucosa contains T cells and APCs with the few immune cells present 
consisting primarily of CD1a+ DCs and CD8+ intraepithelial lymphocytes (IELs) (117). The 
tissues in the UGT have been found to express a greater number Th1-associated chemokines 
than the tissues in the LGT comprising the cervical-vaginal region (117). The menstrual cycle 
and menopause have been reported to have no apparent effect on cellular localization or 
abundance of T lymphocyte subsets and APCs in any of the lower genital tract tissues (118). 
Migration of T lymphocyte subsets is vital for adaptive immune responses and is the result 
of host-pathogen interactions. Effector lymphocytes must be recruited to the FGT after 
activation in the local iliac lymph nodes (118). To eradicate pathogens from the infected 
genital tract, effector T cells must migrate back to the FGT (117, 118). Following infection of 
the mucosal epithelial cells of the FGT the pathogen induces release of host factors 
modifying the adhesion cascade.  Following chlamydial infection of the murine FGT, 
increased expression of an adhesion molecule (119) and expression of Th-1 associated 
chemokines (120) has been reported. The release of host factors in turn influences the 
recruitment of lymphocytes to the infection site. These host factors act to modify the 
specific T lymphocyte subsets recruited to the FGT in response to infection. In humans, 
women with cervicitis and vaginitis have been reported to have increased numbers of 
intraepithelial CD8+ and CD4+ lymphocytes and APCs in the vaginal mucosae when 
compared to women having no symptomatic infections at these mucosal sites (117). 
In mice, investigations into the distribution and function of T lymphocytes in the FGT have 
reported that 70-90% of the lymphocytes in the uterus and upper parts of the cervix of 
C57BL/6 mice are extrathymically-derived CD3+αβTCR+CD4-CD8-T cells  (121). In the murine 
vaginal tract, 30-40% of the T lymphocytes have been reported as being mostly CD4+ T cells 
[see mini-review (18)]. Hormonal control of cytokine secretion by vaginal and uterine 
lymphoid cells has been investigated in two strains of mice (Balb/c and C57BL/6) and it was 
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reported that the numbers of IFN gamma-secreting vaginal and uterine lymphoid cells 
increased at diestrous in both strains of mice (122). Female C57BL/6 mice were also used to 
show that estrogen–conditioned bone marrow derived dendritic cells (BM-DC) could 
enhance regulatory T cell (Treg) activity and also directly inhibit effector T cells in the 
absence of Treg cells (123).    
 
In humans, expansion of human CD4+CD25+ regulatory T cells (Tregs) has been reported to 
occur in the late follicular (proliferative) phases of the menstrual cycles of fertile women 
(30). This increase in Tregs was correlated not only with normal serum levels of E2 in these 
women but also with an increased expression of the Foxp3 gene (31).  Interestingly, E2  is 
reportedly responsible for the elevated immune-suppressive potential of Tregs (124).   
  
Increased expression of FoxP3+ mRNA was seen primarily in the FGT of mice following 
infections of the genital tracts of these animals with C.trachomatis serovar D (32).  It is 
generally accepted that Treg cell expansion is modulated by E2 (30) and  may be associated 
with reduced cell mediated immune responses. Thus it seems that increased levels of P4 
during the menstrual cycle (and progestins delivered via  hormonal contraceptives) may 
have profound effects  on the outcomes of bacterial infections of the female genital tract, 
including those caused by  Chlamydia, by increasing Treg freqencies and lowering CMI 
responses in these infected populations (125). Infections of the human FGT with 
C.trachomatis are, however, less likely to occur in P4 dominant conditions. This is due to the 
fact that as previously mentioned the vaginal epithelia of humans is not as permeable to 
antigen uptake during the P4-associated luteal phase of the menstrual cycle since P4 does 
not significantly thin this mucosal epithelium. 
 
Decreases in the numbers of Tregs have been reported in endometrial samples of 15 
progestin-treated patients with atypical endometrial hyperplasia. In these same patients, , 
progestin treatment was associated with significant increases in cytotoxic T cell activity, 
suggesting that sub-populations of lymphocytes can be affected by progestins (126).  P4 and 
to a lesser extent, E2, have both also been reported to reduce Foxp3+ Treg cells in 
peripheral blood mononuclear cells (PBMC) in  in vitro systems that represented the second 
trimester of human pregnancies (127).  T cell activation signalling (by CD3zeta, JAK2 and 
JAK3 proteins) and cytokine production in cells exposed to hypoestrogenic (4pg/ml of E2) 
postmenopausal  levels of E2 were shown to diminish significantly and this correlated with 
reduced IL-2 production in Jurkat 6.1 T cells (128). This latter finding highlights the fact  that 
a reduction in levels of E2 after menopause can and does contribute to immunosenescence.  
 
T lymphocyte activity in the human uterus is also influenced by the menstrual cycle; for 
example CD3+CD8+ CTL activity is detectable during the proliferative phase but absent 
during the secretory (postovulatory) phases of fertile women (26).  In postmenopausal 
women strong CD3+ T cell cytolytic activity is detected in all compartments of the FGT. 
These findings suggest that the high levels of E2 and P4 present during the proliferative 
phase of the menstrual cycle can down-regulate CTL activity in the uterus. Studies show that 
E2 greatly increases the activity of the IFN-γ promoter in human T cell lines suggesting that 
E2 may favour Th1 responses. Receptors for E2 have also been shown on both CD8 and CD4 
T cell populations (127).  
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Hormonal fluctuations during the estrous cycle that affect cell mediated immunity in the 
upper FGT may also potentially play a major part in making this mucosal site distinctively 
susceptible to chlamydial infections (129,130).    
 
The FGT of humans and of rodents differs in many ways that can modulate the immune 
responses at this mucosal site. Both human and rodent genital tracts have large numbers of 
dendritic cells; however, only the human FGT contains large numbers of CD4+, CD8+ T cells, 
B cells and macrophages. Leukocyte subpopulations are found throughout the human FGT 
and include T helper cells (TH1, TH2, TH17), cytotoxic T cells, Treg cells, NK cells and γδ T 
cells. In contrast to rodents, the numbers of T cells in the vagino-cervix mucosae of women 
does not change during the various phases of the menstrual cycle. Cytotoxic T cell activity in 
the cervix and vagina of women is demonstrated during all phases of the menstrual cycle.  
 
Thus, both the human lower (LGT) and upper genital tracts (UGT) are immunologically active 
throughout the normal menstrual cycles of women.  Localisation of T-lymphocyte 
populations in the human female UGT and LGT and the effects of menstrual cycle phases 
and of chlamydial infections on these immune cells is summarised (Table 1). 
5.  Hormonal regulation of immunoglobulin secretion 
In humans the predominant antibody isotype in female cervicovaginal secretions is 
immunoglobulin (Ig)G (131) although secretory IgA (SIgA) in the polymeric form is also 
present (132).  Levels of IgG and IgA antibodies in FGT fluids are modulated by the stage of 
the menstrual cycle in women and the estrous cycle in rodents.    
It is known that the neonatal Fc receptor, FcRn, in the genital epithelium mediates transport 
of IgG into the FGT and that local levels are affected by stage of the murine estrous cycle, 
with highest levels being recorded at diestrous (133). The transport of IgG into the Fallopian 
tubes and uterus is also significantly decreased by P4 treatment and this is likely correlated 
with FcRn expression (134). 
Mucosa-associated epithelial chemokine (MEC) CCL28 can recruit IgA plasma cells to the 
uterus of the murine reproductive tract following mucosal (intranasal or vaginal) 
immunizations and this migration is dependent upon E2 (135).  Interestingly, the IgA plasma 
cells induced by mucosal vaccination were recruited to the uterus, but not to the cervix or 
the vaginal canal.  E2 also up-regulates the in vitro expression in the FGT of secretory 
component (SC) increasing transport of IgA into the lumen (136) and transport of polymeric 
IgA (pIgA) into FGT tissues is significantly decreased by ovariectomy,  although this  decline 
can  be reversed by addition of E2 but not P4 (134).  
The levels of Igs in genital tract secretions of women vary during the menstrual cycle with 
the lowest levels of IgG occurring around the time of ovulation in women with HPV-16 
vaccine specific antibodies with total IgG and IgA titers in cervical fluid highest in the 
proliferative phase of the cycle (137,138). In normal cycling female macaques it has been 
reported that the frequency of Ig-secreting cells (ISC) was significantly higher in tissues 
collected from animals in the peri-ovulatory period of the menstrual cycle than in tissues 
collected from other stages of the cycle and that this effect was apparently due to the 
action of estrogen on CD8+ T cells  (139).  The effects of ovarian hormones on (ISC) function 
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in healthy women were also investigated and it was reported that ISC frequency in PMBC 
was highest during the peri-ovulatory stage of the menstrual cycle (140).  
In murine studies, not surprisingly, it has been shown that E2 influences immunoglobulin 
levels in post-pubertal female C57BL/6 (B6) mice, with these animals expressing genes 
involved in adaptive immune responses including IgA, IgG1 , IgG2 and B-cell receptor gene 
involved in B cell signalling (141). In female BALB/c mice, E2 strongly stimulated the 
production of  bovine serum albumin (BSA)-specific antibodies (mostly of the IgG1 isotype) 
in the sera of BSA-immunised mice (142). A study of the effects of sex hormones on 
migration of antibody-secreting cells into the genital tracts of female BALB/c mice revealed 
that the mRNA expression from adhesion molecules and chemokines ICAM-1, P-selectin and 
JAM-1 was significantly increased in ovariectomised mice and that these changes were 
restored to normal levels by E2 treatment (143). 
The maturation, selection and activation of B cells is also known to be affected by estrogen 
treatment with E2 shown to alter the later stages of B cell development (reviewed in 144). 
Recently it has been reported that in female B-cell deficient mice that do not express IgM,  
E2 increased the frequency of IgA producing plasma-cells suggesting that E2 can influence 
an alternative B-cell pathway found in these mice (145). 
IgA secreting plasma cells typically produce dimeric IgA (dIgA) and once secreted into the 
lamina propria dIgA binds the polymeric immunoglobulin receptor (pIgR) at the basolateral 
surface of mucosal epithelial cells forming secretory IgA (SIgA). It is known that dIgA:pIgR 
complexes can neutralize intracellular pathogens such as HIV (146) although the precise 
effects of these complexes on chlamydial infections is presently unknown. The pIgR is 
ubiquitously expressed by epithelial cells in the human FGT with high expression observed in 
the UGT (147).  Innate (mediated by TLR3) and adaptive immune responses (including IFN-γ) 
to infection are known to regulate pIgR expression. Additionally the sex hormones E2 and P4 
also play regulatory roles in expression of the pIgR. In female rats E2 is known to up-regulate  
the pIgR expression (148) although in primates ovulation coincides with a decrease in 
mucosal antibodies (136). The sex hormone P4 down-regulates pIgR expression in rats (149) 
and although the specific role of the pIgR in chlamydial infections is debatable the 
protective role of IgA and the pIgR may indeed be of importance in the development of 
subunit vaccines against C.trachomatis. 
6. Sex hormones and genital tract infection 
It is becoming increasingly well documented that sex hormones E2 and P4 regulate host 
susceptibility, as well as innate and adaptive immune responses, to sexually transmitted 
pathogens infecting the mucosal surfaces of the FGT. STD pathogens that infect this site 
include viruses (HIV-1, HSV-2, HPV) and bacteria such as Neisseria gonorrhoeae and 
Chlamydia trachomatis. There are numerous reports in the literature on studies in women 
and in animal models that report the effects of sex hormones on genital tract infections 
caused by these mucosal pathogens (e.g. for HIV review see 150).   
In this review we will specifically focus our discussions on Chlamydia trachomatis as this 
organism is the perennial target for much of our own research.  
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Chlamydia trachomatis 
The columnar epithelial cells of the FGT are target cells for chlamydial infection and 
although natural immunity to infection with this mucosal pathogen does occur, it is serovar-
specific and short-lived. Local host defence against Chlamydia involves the mucosal barrier 
comprised of epithelial cells and mucus and innate, humoral and cell-mediated immune 
responses (Figure 3).  Decreased levels of SLPI in vaginal secretions are reportedly inversely 
related to infections caused by C.trachomatis (151) but  SLPI expression is reportedly 
induced following C.trachomatis infection of the FGT (152) and elafin mRNA expression is 
up-regulated in a Chlamydia-infected oviduct epithelial cell line (62) (see Table 3, 152-155)   
Infection of the FGT with live replicating C.trachomatis is innately recognized by surface 
PRRs TLR2 and TLR4 that are highly expressed in the UGT tissues (44). The myeloid 
differentiation primary response gene (MyD)88 is essential for nuclear factor–κ-β (NFκβ) 
signalling and transcription of proinflammatory cytokines. Along with TLR2, MyD88 
specifically co-localises with the intracellular chlamydial inclusion (156) Additional to the 
TLRs the NOD-like receptor, NOD1 also senses chlamydial infection of endocervical epithelial 
cells. Signals transduced from these TLRs lead to induction of IFN-g and cytokine genes that 
contribute to resolving chamydila genital infection in an IFN-g dependent manner, noting 
also that TLR2 is also responsible for severe tubal immunopathology in a murine model  and 
that the chlamydial plasmid plays a crucial role in TLR2 activation(157, 158). In response to 
chlamydial infection, epithelial cells secrete pro-inflammatory cytokines/chemokines such 
as IL-6 and IFN-g that are hypothesised activators of pathology in the cellular paradigm of 
chlamydial pathogenesis (159). 
 
Chlamydia trachomatis infection of the female LGT stimulates innate immune cells by 
activation of TLR2/TLR 4 (reviewed in 160).  TLRs 2 and 4 have been found at the highest 
expression levels in endometrium and Fallopian tube tissue (161) with the predominant 
expression of TLR4 and its co-receptor CD14 in the Fallopian tubes proposed to play an 
important role in the innate host defence mechanism against ascending C. trachomatis 
infections (160, 162). In a recent study C.trachomatis-infected women have been reported 
to express higherTLR2, LR4 and inducible nitric oxide synthase iNOS in their cervical 
monocytes compared to controls. It is thought that TLR4 initiates the innate immune 
response to chlamydial infection, activation of TLR2 leads to expression of inflammatory 
cytokines whilst iNOS contributes to chlamydial clearance from this mucosal site (163). 
 
Studies into C.trachomatis infections of the FGT have reported many effects of hormones on 
infection and immunity to the pathogen at this mucosal site. For example significant 
increases in the sensitivities of cervical epithelial cells to infection with C.trachomatis occur 
in the later stages of the female menstrual cycle (164). It has been reported that chlamydial 
infection occurring in the early E2-dominant phases of the cycle was a significant predictor 
for development of salpingitis (165). Clinical findings have also reported on the enhancing 
effects of E2 on chlamydial infection and disease sequelae in the infected female genital 
tract. It has been reported that women are more susceptible to chlamydial infection under 
the influence of E2 (28).  In women with fertility disorders (n= 115) and in women with 
C.trachomatis mucopurulent cervicitis (n=86) a significantly positive correlation was 
recorded between chlamydial load and E2 levels (14).  
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Hormones can also affect the immune responses to chlamydial infections of the FGT in mice. 
A recent seminal study has reported that IFN-ε -/- mice showed significantly increased levels 
of chlamydial growth in the upper reproductive tracts at 30 days post intravaginal infection 
with C. muridarum. The mice also showed more severe clinical signs of disease following 
intravaginal infections with sub-lethal doses of C. muridarum. IFN-ε expression is also 
hormonally regulated. The presence of high levels of E2 (proliferative phase) coincided with 
the highest expression levels of IFN-ε and E2 administration to ovariectomised mice induced 
a six-fold increase in IFN-ε expression. Thus, IFN-ε constitutively expressed by luminal and 
glandular epithelial cells of the endometrium can protect against Chlamydia without 
aggravating disease - the first report that indicates a Type 1 interferon can protect and not 
worsen a chlamydial genital tract disease (69). 
Chemokine receptors direct T lymphocytes to the site of mucosal infection, including 
infection of genital tract epithelial cells with C.trachomatis and these receptors can be 
modulated by E2.  In a study examining samples from human patients it was reported that  
CCR5 expression increased followed C. trachomatis genital infections (21).  It is also now 
known that CXCR3 (chemokine (C-X-C motif) receptor 3) and CCR5 (chemokine (C-C motif) 
receptor 5) are the predominant receptors that are crucial for T-lymphocyte access to the 
genital tract during a Chlamydia trachomatis infection in a murine model (166). Therefore, 
the protective capacity of Chlamydia-specific T cells in the genital tract can be modulated by 
the sex steroid E2. 
 
Reproductive hormones may potentially act with cytokines to regulate immune responses in 
the FGT to chlamydial genital tract infections in vivo. Significant negative correlation has 
been reported between E2 levels in women with primary chlamydial genital infections and 
cervical wash concentrations of IL-10, IL-1beta and IL-6 cytokines.  Significant negative 
correlation was also recorded between IL1-beta cytokines and P4 levels in women with 
recurrent chlamydial infections (167). Thus it would appear that chlamydial infection of the 
human FGT is modulated in part by the combined actions of cytokines with E2 and P4. More 
recent investigations reveal that levels of E2 were significantly higher in Chlamydia positive 
women with fertility disorders when compared to fertile women suggesting that this sex 
hormone contributes to development of disease sequelae to C.trachomatis infection of the 
FGT (28). 
 
Results of studies into the course of genital chlamydial infections in animal models have also 
revealed the effects of reproductive hormones on immune responses and disease sequelae. 
Results of these studies have validated much of the clinical data for chlamydial genital 
infections in women.  In mice, significantly more chlamydiae were recovered from the 
uterine horns and oviducts when animals were infected during periods of increased levels of 
P4 and E2 (secretory phase) rather than when infections occurred during the follicular phase 
(168).   Rank and colleagues (129) reported that high E2 levels in guinea pigs corresponded 
with a significantly greater percentage of Chlamydia-infected animals developing oviduct 
pathology. It was also reported that high doses of P4 did not alter the course of genital 
infection in guinea pigs (130) but other reports using different animal models showed that 
these doses increased the rate of infection, for example using a rat model (169) and also 
that high doses of P4 resulted in more intense C.muridarum infections of mice (170). 
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Attachment and infectivity of chlamydial elementary bodies (EBs) in vitro reportedly has 
been enhanced by E2 for HeLa cells (171), human endometrial epithelial cells (172), luminal 
epithelial cells from swine genital tracts (173) and oestrogen-responsive endometrial 
carcinoma cell lines Ishikawa and HEC1B and breast cancer lines (174). In vivo, epithelial 
cells have been reported to be more sensitive to C.trachomatis serovar E in the E2-dominant 
(proliferative) stage of the human menstrual cycle than at other stages of the cycle (175, 
176).  More recently preliminary work from our own laboratory has investigated infection of 
ECC-1 human endometrial cell lines with C.trachomatis serovars D and L2 supplemented 
with 200pg/ml E2 or 20ng/ml P4. We report that P4 up-regulates adhesion molecules 
involved in cell recruitment (CX3CL1, E-selectin, ITGB8 and others) and down regulates 
interferon and interferon receptor genes. Our results indicate that the gene expression 
patterns induced by E2 in this system are suggestive of persistent chlamydial infection (177). 
Hormonal contraceptive use in women, particularly depo medroxyprogesterone (DMPA), 
has also been reported in observational studies to be associated with a four-fold increase in 
chlamydial genital tract infections (178) although the biological explanation for increased 
risk of infections caused by DMPA has been challenged (179). A feasibility plan recently has 
been conducted to pave the way for a future randomised trial to investigate hormonal 
contraception and the risks of STI acquisition in women (180).  
Thus in terms of developing a protective mucosal vaccine for Chlamydia it is, therefore, 
prudent to consider the influences of sex hormones on infection and immune responses to 
C.trachomatis within the female genital tracts both of humans and of animals. 
 
7. Sex hormone influence on vaccine-induced immunity 
Many studies examining the effects of sex hormones on vaccine-induced immunity against 
sexually transmitted pathogens have been conducted using the murine model with animals 
that undergo an estrus cycle. The cycle consists of Proestrus and Estrus, in which follicles 
grow and mature, the endometrium develops, and an estrogen surge occurs in conjunction 
with ovulation. In Metestrus the corpus luteum and high levels of progesterone are seen, 
and during Diestrus the corpus luteum regresses. In estrus it is also seen that the 
endometrium is reabsorbed if conception does not occur whilst in the human menstrual 
cycle the endometrium is shed. It is to be noted, however, that with respect to chlamydial 
infections of the FGT there are many differences between the murine models using C. 
muridarum and the pathogenesis of human C.trachomatis endocervical infections.  Two 
examples of these differences are (i) the strain of chlamydia used in the mouse model which 
is not a natural pathogen of the murine FGT, and (ii) Th1 immunity to C.muridarum in the 
mouse model that causes significant damage to the upper genital tracts of mice whilst in 
endocervical infections of women with C.trachomatis upper genital tract damage occurs 
infrequently. 
 When E2 prevents the penetration of antigen into the vaginal epithelium by increasing the 
mucosal barrier thickness it reduces the antigen-loading of vaginal antigen presenting cells.  
E2 thus inhibits the crucial process of CD8+ T cell priming, although antigen uptake can still 
occur in the vaginal mucosa following removal of the mucus layer at this site   Interestingly, 
when antigen is administered orally or intranasally during the E2-dominant phases of the 
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estrus cycle, specific antibodies in the female genital tract are significantly enhanced (181). 
The ability to prime CD8+ T cells after immunization at the progesterone-treated genital 
tract is strongly infkuenced by ovarian steroid hormones (182). Thus it needs to be 
remembered that sex steroids can modulate immune responses following intravaginal and 
intranasal routes of immunization, routes that are more effective at eliciting genital tract 
antibody responses than parenteral immunization.  
Song and colleagues investigated the effects of exogenous E2 administration, following 
intravaginal inoculation of BALB/c mice with N. gonorrhoeae, and they found an increase in 
gonococcal-specific serum antibody in these animals (183).  Others have found that E2 
treatment increased the specific antibody response to Dinitrophenyl–keyhole limpet 
hemocyanin (DNP–KLH), a T-cell-dependent antigen, in BALB/c mice. By experimenting with 
agonists to each of the E2 receptors (ERα and ERβ), they determined that the effects of E2 
on antibody production are mediated via signalling pathways involving both ER receptors 
(184). It appears that the timing between E2 administration and immunization or challenge 
doses can affect the ability of the antigen/micro-organism to penetrate the mucosal 
epithelia; choice of mouse strain may also affect these processes. 
Protection against several STI’s including C.trachomatis requires not only the stimulation of 
IgG and IgA antibodies but also antigen-specific CD4+ T-cells in the genital tract. However 
our knowledge is rudimentary regarding both T-cell responses the effects of sex steroids 
following mucosal immunizations to induce these responses in the FGT. A recent study 
investigating live chlamydial genital tract infections in the murine model reported that P4 is 
required for an effective, protective T-cell response in the genital tract following intravaginal 
immunizations, but that E2 prevented a response (32). Thus CD4+ T-cell immunity in the FGT 
can indeed be induced by local mucosal immunisation with appropriate chlamydial 
immunogens (e.g. MOMP) and adjuvants (e.g. CTA-DD) as has recently been reported 
(185).Optimal protection at this site will require knowledge of the ovarian steroid status at 
the time of immunization in attempts to elicit protective immunity against a live genital 
tract infection with Chlamydia. 
In non-human primates, studies have shown that live attenuated lentivirus (simian-human 
immunodefiency virus) protects 60% macaques against challenge with intravaginal simian 
immunodeficiency virus (SIV). Depo-provera pre-treatment of the animals resulted in a 
decrease in this protection (186) a finding that is similar to that observed in mice. 
Finally, only a limited number of studies to date have examined the effects of sex hormones 
on vaccination outcomes in females. Women that were given vaginal immunizations with 
bacterial lipopolysaccharide (LPS) during either the E2-dominant follicular or the P4-
associated luteal phases of the ovarian cycle only induced cervical IgA2-restricted antibodies 
against LPS when immunised during the follicular phase of the cycle (187). Women that 
were given intra-vaginal immunizations with a recombinant Cholera toxin B subunit and 
immunogen showed no differences in their resulting immune responses to the antigen 
whether they were using P4-containing intra-uterine devices, on the oral contraceptive pill, 
or were using no contraception at all (188).  These results indicate that the magnitude of the 
immune responses elicited in the FGT could be influenced by the phase of the menstrual 
cycle for intra-vaginally administered vaccines. 
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Summary 
 
The female genital tract is a site of abundant immune processes having an extensive 
lymphoid system capaale of mounting a protective immune response to intracellular 
pathogens such as Chlamydia trachomatis. The effects of ovarian steroid hormones on 
innate immunity, antigen presentation, T cell-specific immunity and immunoglobulin 
production have been examined with some studies that have been highlighted presenting 
contradictory findings to other studies discussed. The contrary reports are likely due to the 
variety of cell lines and models used in the experimental investigations, and also due to 
varying levels and combinations of hormones tested in these studies.  
 
This review highlights and updates our current knowledge of the effects of ovarian steroid 
hormones on various components of immune responses in the FGT and how these 
responses can modulate susceptibility of this mucosal site to STI’s. Future investigations into 
vaccines to control infections of the female reproductive tract will need to consider the 
effects both of E2 and of P4 at this mucosal site.  Animal models and in vitro assays should 
continue to be refined in design with respect to sex hormone status in attempts to more 
accurately reflect the potential efficacy of novel vaccine preparations tested in these models 
that are destined for use in humans. 
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Table 1 
Localisation of T Lymphocytes in the Female Upper (UGT) and Lower (LGT) Genital Tracts: effects of Menstrual Cycle Stage and Chlamydial infection  
T Lymphocytes Upper Genital Tract (UGT) Lower Genital Tract (LGT) Menstrual Cycle Stage 
(Ovarian phase) 
 
 
 
Ovaries Fallopian 
Tubes 
Uterus/ 
Endometrium 
Endocervix Ectocervix Vagina Proliferative 
(Follicular) 
Secretory 
(Luteal) 
 
Chlamydia 
trachomatis 
 
Genital tract 
Infection 
 
 
 
References 
 
Serum 
estradiol  
      220pmol/L <130pmol/L 
Progesterone       <2ng/ml >5ng/ml 
T helper cells          
CD45+, CD3+,  
CD4+ 
TH1, TH2, TH3, 
TH17 or TFH 
 CD45+cells 
 
CD3+CD8+ 
>% than 
CD3+CD4+ 
 
 
CCR5+CD4+ 
CD3+ 
 
CD45+ 
CD3+, 
CD4+ 
CD3+ 
CD4+ 
CD4+ 
(30-40% 
of 
vaginal 
T cells) 
CD3+ 
CCR5+ (+) 
 
CD45+  
leukocytes 
(+) 
(mid-luteal) 
CCR5+ (+) 
 
CD45+ 
leukocytes 
(+) 
(mid-luteal) 
Endocervix: 
CD4+ cells 
(++++) 
 
Endometrium 
CCR5 and 
CD103 
cells(+) 
 
Cervix 
CD3+CD4+ 
Kaldenso (2011) REF#17 
Hamad (2008) REF#18 
Shaw et al., (2011 )REF#19 
Disep et al., (2004) REF#20 
Ficarra (2008) REF#21 
Johannsen etal(1999)REF#22                            
Kamat & Isaacson (1987) REF#23 
Starkey et al.,(1991) REF#24 
Vassiliadou &Bulmer (1996) #25 
Agrawal et al.,(2008) REF#28 
CytotoxicT cells           
CD45+, CD3+,  + CD3+ CTL + + + 
↑ (uterus) 
↓(uterus)  
White et al., (1997a) REF#26 
CD8+ 
 
 
 
 CD8+ 
CTL 
activity 
CD8+CTL 
activity 
 
 
  (+++) 
>50% 
vaginal 
T cells 
 
 
 
 
↓CTL 
activity (no 
change in 
CD8+cell#) 
CD8+ cells 
Cervix 
CD3+CD8+ 
White et al., (1997a) REF#26 
Li et al (2009) REF#27 
Ficarra (2008)  REF#21 
Johannsen et al.(1999) REF#22 
Agrawal et al.,(2008) REF#28 
  CD8+ CTL  CTL 
activity 
 CTL 
activity 
measurable measurable  
White et al .,(1997b) REF#29 
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(+) symbol indicates presence of T cells in the UGT  and LGT over the menstrual cycle with increasing numbers of (+) symbols indicating increased  cell 
numbers 
   CD8+CD4- 
 
      
Yeaman et al., (1997) REF#9 
Treg cells           
Natural 
CD4+,CD25+ 
FoxP3+ 
 
Adaptive 
Tr1 and Th3 
 
 
  +     ↑levels 
correlating 
withE2 
(uterus) 
↑levels 
(E2 at 
physiologic 
doses) 
↓levels 
Significant 
after 
ovulation 
↓levels 
(E2 at 
physiologic 
doses) 
Increased 
expression 
of FoxP3+ 
cells 
primarily in 
UGT 
 
Arrivito et al., (2007) REF#30 
Tai et al., (2008) REF#31 
Marks et al., (2010) REF#32 
 
γδ T cells           
Intraepithelial 
Lymphocytes  
(IELs) 
  IELs stromal 
CCR5+ CD4+  
      Kaldenso et al., (2011) REF#17 
Memory T 
cells 
        Endocervix: 
α4β7+ 
Cutaneous 
Lymphocyte 
Antigen 
(CLA)+ 
Kelly et al., (2009) REF#39 
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Table 2: Innate Immunity in the human FGT: The effects of menstrual cycle phase 
(proliferative or secretory) on the levels (↑= increased, (=) =constant or ↓= decreased) and 
functions (activity) of innate immune cells, non-immune cells and soluble factors   
Lower Genital Tract 
(LGT) 
(Ectocervix & Vagina) 
Proliferative 
(E2 dominant) 
Secretory 
(P4 dominant) 
 
 
References 
Soluble factors  
(AMPs ,HBD2, elafin) 
↓HBD2 and elafin ↑SLPI 16,58 
Epithelial Cells  
(multilayered, squamous) 
Thick vaginal epithelium Thinner vaginal epithelium 9 
Neutrophils (=) (=) 52, 59 
Macrophages Vagina  (=) Vagina (=) 59 
NK cells (CD45+,  CD56+ 
CD3- CD16+) 
(=) (=) 19, 24 
 
Upper Genital Tract 
(UGT) 
(Endocervix & Endometrium, 
Fallopian tubes & Ovaries) 
Proliferative 
(E2 dominant) 
Secretory 
(P4 dominant) 
 
 
References 
Soluble factors 
(AMPs, HBDs, elafin) 
↑HBD4 (endometrium) 
(note: HBD2 and elafin peak 
during menstruation) 
SLPI and elafin (Fallopian 
tubes-constitutively 
expressed) 
↑SLPI, HBD1, HBD3 
(endometrium) 
(maximal expression)  
 
 
60, 61 
 
 
 
 
62 
PRRs (TLR, NOD-1,2) TLR10 (Fallopian tubes) 
TLRs1-7 but not TLR4 
(Endocervix) 
 
TLRs 2,3 5, 6, 9 including 
TLR4) ↑ (endometrium),  
TLR10 ↑ (Fallopian tubes) 
 
63, 64, 54, 65, 
66, 67, 68 
Epithelial Cells 
(single layer, columnar) 
Thick uterine epithelium 
 
Constitutively express IFN-ε 
(Type 1 IFN) in luminal and 
glandular cells highest in 
proliferative phase# 
Thin uterine epithelium 9, 69 
 
 
Neutrophils (=) Endometrial ↑  53, 70, 59 
Macrophages  Endometrial ↑  
(before menstruation) 
24 
Dendritic Cells CD83+ (=) CD1a+↑ 71 
NK cells 
CD45+,  CD56+ 
CD3- 
CD16-, 
CD69+ CD94+ 
 
uNK  ↑CTL activity 
 
Endometrial NK cells (with 
NKG2D receptor)↑MICA  
uNK ↓CTL activity via IL-18 
19, 24, 33-39 
AMPs = Antimicrobial Peptides, HBD2 = Human β Defensin 2, SLPI = Secretory Leukocyte 
Protease Inhibitor, NK = Natural Killer cells, CD = Cluster of Differentiation, PRR = Pattern 
Recognition Receptor, TLR = Toll-like receptor, NOD = nucleotide binding oligomerization 
domain, NKG2D = an activating receptor expressed on NK cells that binds to MHC Class 1 
chain related protein A and B (MICA and MICB), uNK = uterine Natural Killer cell, CTL = 
Cytotoxic T Lymphocyte, IL= interleukin 
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Table 3: Chlamydia trachomatis and Antimicrobial Peptides (AMPs) 
Study Experimental findings 
 
Chlamydia stimulates AMP expression 
 
King et al., 2009 REF62 
 
In vitro – infection of oviductal epithelial cell line results in increased 
elafin expression, but no effect on SLPI 
 
Wheelhouse et al., 
2008 REF152 
In vitro – infection of HeLa (cervical epithelium) and JEG-3 
(trophoblast) cells results in increased SLPI expression 
 
 
AMP activity against Chlamydia 
 
Pal et al., 2006 REF153 In vivo – MMP-7 knockout mice (with reduced α-defensin activity) 
were unaffected in their ability to clear chlamydial infection 
 
Oberley et al., 2004 
REF154 
In vitro – surfactant protein D protein inhibits the infection of HeLa 
cells (an endocervical epithelial cell line by C.trachomatis 
 
Yasin et al., 2002 
REF155 
In vitro – rabbit defensin (NP-1), HNP-2 and porcine leukocyte 
Protegrin reduced chlamydial infection 
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Figure 1: The Female Genital Tract: anatomy and innate immune cells of the genital mucosa 
Figure 1 Legend:This figure depicts non-immune and innate immune cells found throughout the 
female genital tract including macrophages, dendritic cells, neutrophils and NK cells.  Immune cell 
receptors are shown on immune cells. Note that epithelial cell receptors CD4, CCR5, CXCR4 and GalC 
on endometrial and endocervical cells are not shown in this Figure. 
Figure 2: Menstrual Cycle phases, sex steroid levels and effects on innate immune cells in the FGT 
Figure 2 Legend:This figure depicts the immune cell types and their relative abundances  across the  
E2 dominant (proliferative) and P4 dominant (secretory) phases of the menstrual cycle 
Figure 3: Immune protection against chlamydial infection in the female genital tract  
Figure 3 Legend  Innate, humoral and cell-mediated immunity act in concert to protect against C. 
trachomatis infection of non-immune host genital epithelial cells and local innate immune cells in 
the female  genital tract. The hormones estradiol and progesterone regulate innate and adaptive 
immunity against genital chlamydia by promoting mucus secretions, regulating immune and non-
immune cell numbers and activities (Fig. 2) and by altering cell receptor expression at this mucosal 
site.  
Innate  
The epithelial barrier is relatively ineffective at protecting against Chlamydia as this mucosal 
pathogen has a myriad of mechanisms to evade barrier protection.  A mucus layer containing a 
variety of antimicrobial factors and endogenous microbiota contributes towards regulating the pH of 
the FGT to protect against genital tract pathogens. Innate immune cells constitutively secrete an 
array of soluble antimicrobials including SLPI, HBD2, lysozyme, lactoferrin, Elafin, cathelicidins.  
Chlamydial infection of columnar epithelial cells and local  genital tract immune cells including 
neutrophils, macrophages and  natural killer (NK) cells produces soluble antimicrobials ,chemokines 
and pro-inflammatory cytokines that selectively prevent bacterial infection of target host cells.  (e.g. 
IL-1 released from infected epithelial cells promotes Th17 differentiation).  Recruitment and 
activation of adaptive immune cells (B and T cells) is also orchestrated by the release of these 
secreted soluble antimicrobial factors from epithelial cells, DCs and macrophages. 
Humoral 
Antibodies potentially can prevent infection by Chlamydia. IgG is the predominant antibody in the 
FGT. Antibodies released from plasma cells (P IgG and P IgA) inactivate extracellular chlamydial 
elementary bodies (EBs). 
Cell-Mediated 
CD4+ T cell production of IFN-g contributes to host defence by inhibiting intracellular chlamydial 
replication. Cell mediated immunity induces apoptosis of infected cells by cytotoxic CD8+ T cells. 
References: 13, 28, 32, 39, 62, 63, 77, 118-121,152-159, 174 
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